WALTHAM, Mass., Aug. 31, 2011 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD), a company focused on the development and commercialization of novel, biomarker-based diagnostics, announced today that results from two preclinical studies were presented at the European Society of Cardiology (ESC) Congress 2011, in Paris, France. The studies utilized genetic and pharmacological methodologies to investigate the role of galectin-3 in heart failure. One of the studies used a natural selective galectin-3 inhibitor to investigate whether blocking galectin-3 can attenuate heart failure development and reduce mortality. Both studies were presented by Lili Yu, MD, Research Fellow, Department of Cardiology, University Medical Center Groningen, University of Groningen, The Netherlands.
